Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on May 21, 2009

Arteriosclerosis, Thrombosis, and Vascular Biology. 2009
Published online before print May 21, 2009, doi: 10.1161/ATVBAHA.109.186742
A more recent version of this article appeared on August 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
29/8/1185    most recent
ATVBAHA.109.186742v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walshe, T. E.
Right arrow Articles by D'Amore, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walshe, T. E.
Right arrow Articles by D'Amore, P. A.
Right arrowPubmed/NCBI databases
*Substance via MeSH

Submitted on July 16, 2008
Accepted on May 11, 2009

Inhibition of VEGF or TGF-{beta} Signaling Activates Endothelium and Increases Leukocyte Rolling

Tony E. Walshe ; Vandana S. Dole ; Arindel S.R. Maharaj ; Ian S. Patten ; Denisa D. Wagner ; and Patricia A. D'Amore *

From the Schepens Eye Research Institute and Harvard Medical School (T.E.W., A.S.R.M., P.A.D.), the Immune Disease Institute (V.S.D., I.S.P., D.D.W., P.A.D.), and the Department of Pathology, Harvard Medical School (V.S.D., D.D.W., P.A.D.), Boston, Mass.

* To whom correspondence should be addressed. E-mail: patricia.damore{at}schepens.harvard.edu.

Objective—Motivated by the central roles that vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-{beta} play in the assembly and maintenance of the vasculature, we examined the impact of systemic VEGF or TGF-{beta} signal inhibition on endothelial activation as detected by leukocyte-endothelial interactions.

Methods and Results—VEGF or TGF-{beta} inhibition, accomplished using adenovirus expression of soluble Flt1 (Ad-sFlt1) or soluble endoglin (Ad-sEng), resulted in a significant increase in the number of leukocytes rolling along the mesenteric venous endothelium and a significant decrease in rolling velocity in Ad-sEng mice. Neutralization of VEGF or TGF-{beta} resulted in endothelial surface expression of P-selectin and impaired peripheral vasodilatation. Neither inhibition of VEGF nor TGF-{beta} was associated with platelet or leukocyte activation, as detected by the activation markers platelet P-selectin and the active integrin {alpha}IIb{beta}III, or by leukocyte expression of L-selectin. Soluble vascular cell adhesion molecule (VCAM)-1 and E-selectin were increased in sEng-expressing mice, indicating higher levels of these adhesion receptors.

Conclusions—VEGF or TGF-{beta} neutralization results in impaired endothelium-mediated vasodilatation and elevated expression of surface adhesion molecules, resulting in increased leukocyte adhesion. These results indicate an essential role for both VEGF and TGF-{beta} in maintaining the endothelium in a nonactivated state and have implications for therapeutic approaches that neutralize VEGF or TGF-{beta}.


Key words: VEGF • TGF-{beta} • P-selectin • nitric oxide • inflammation